Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.51 |
| ▸ | HPGD | P15428 | 2/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.51 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.50 |
| ▸ | MAPT | P10636 | 4/20 | 0.50 |
| ▸ | MEN1 | O00255 | 4/20 | 0.50 |
| ▸ | NPC1 | O15118 | 3/20 | 0.50 |
| ▸ | RAB9A | P51151 | 3/20 | 0.50 |
| ▸ | NFKB1 | P19838 | 3/20 | 0.50 |
| ▸ | NFKB2 | Q00653 | 3/20 | 0.50 |
| ▸ | RELA | Q04206 | 3/20 | 0.50 |
| ▸ | GAA | P10253 | 2/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | TP53 | P04637 | 1/20 | 0.50 |
| ▸ | PIK3CD | O00329 | 4/20 | 0.44 |
| ▸ | PIK3CA | P42336 | 4/20 | 0.44 |
| ▸ | PIK3CB | P42338 | 4/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10665450 | 0.81 | KMT2A (0.55) | ALDH1A1KDM4EHPGDPOLBALOX15 | |
| SCHEMBL12004940 | 0.81 | KMT2A (0.49) | ALDH1A1KDM4EHPGDKMT2AMAPT | |
| SCHEMBL925797 | 0.80 | CYP3A4 (0.51) | ALDH1A1KDM4EHPGDKMT2AMAPT | |
| SCHEMBL1886754 | 0.80 | PIK3CG (0.53) | ALDH1A1KMT2AMAPTMEN1NPC1 | |
| SCHEMBL10666409 | 0.79 | KDM4E (0.49) | ALDH1A1KDM4EHPGDPOLBALOX15 | |
| SCHEMBL10670937 | 0.79 | PIK3CG (0.72) | POLBKMT2AMEN1PIK3CDPIK3CA | |
| SCHEMBL27656677 | 0.79 | PIK3CG (0.56) | ALDH1A1POLBKMT2AMAPTMEN1 | |
| SCHEMBL925241 | 0.79 | RAB9A (0.82) | ALDH1A1KDM4EHPGDPOLBALOX15 | |
| SCHEMBL29941155 | 0.78 | CDK2 (0.53) | KMT2ACDK4CDK2CCNA2PLK1 | |
| SCHEMBL10669162 | 0.78 | KDM4E (0.47) | ALDH1A1KDM4EHPGDPOLBALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7868188-B2 | 5-heteroaryl thiazoles and their use as PI3K inhibitors | ASTRAZENECA AB (SE) | 2011-01-11 | — | — | US | disclosed |
| EP-1841763-B1 | 5-HETEROARYL THIAZOLES AND THEIR USE AS PI3K INHIBITORS | ASTRAZENECA AB (SE) | 2010-06-30 | — | — | EP | disclosed |
| CN-101484452-A | Thiazole derivatives and their use as anti-tumour agents | ASTRAZENECA AB (SE) | 2009-07-15 | — | — | CN | disclosed |
| US-20090076009-A1 | THIAZOLE DERIVATIVES AND THEIR USE AS ANTI-TUMOUR AGENTS | ASTRAZENECA AB (SE) | 2009-03-19 | — | — | US | disclosed |
| EP-2016075-A1 | THIAZOLE DERIVATIVES AND THEIR USE AS ANTI-TUMOUR AGENTS | AstraZeneca AB (SE) | 2009-01-21 | — | — | EP | disclosed |
| US-20080132502-A1 | 5-Heteroaryl Thiazoles And Their Use As PI3K Inhibitors | ASTRAZENECA AB (SE) | 2008-06-05 | — | — | US | disclosed |
| CN-101098869-A | 5-heteroaryl thiazoles and their use as p13k inhibitors | ASTRAZENECA AB (SE) | 2008-01-02 | — | — | CN | disclosed |
| WO-2007129044-A1 | THIAZOLE DERIVATIVES AND THEIR USE AS ANTI-TUMOUR AGENTS | ASTRAZENECA AB (SE) | 2007-11-15 | — | — | WO | disclosed |
| EP-1841763-A1 | 5-HETEROARYL THIAZOLES AND THEIR USE AS PI3K INHIBITORS | AstraZeneca AB (SE) | 2007-10-10 | — | — | EP | disclosed |
| WO-2006051270-A1 | 5-HETEROARYL THIAZOLES AND THEIR USE AS P13K INHIBITORS | ASTRAZENECA AB (SE) | 2006-05-18 | — | — | WO | disclosed |
| US-4735957-A | ANTIULCER AGENTS, CARDIOTONIC AGENTS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1988-04-05 | — | — | US | disclosed |
| US-4649146-A | ANTIULCER | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1987-03-10 | — | — | US | disclosed |
| EP-0117082-A2 | Thiazole derivatives, processes for the preparation thereof and pharmaceutical composition comprising the same | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1984-08-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090076009-A1 | THIAZOLE DERIVATIVES AND THEIR USE AS ANTI-TUMOUR AGENTS | MTOR, RPTOR, JAK2 | ALDH1A1 1838/4885KDM4E 2921/4885HPGD 2173/4885 |
| US-20080132502-A1 | 5-Heteroaryl Thiazoles And Their Use As PI3K Inhibitors | MTOR, PIK3R5, PIK3CA | ALDH1A1 2310/4885KDM4E 1979/4885HPGD 3534/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.